M. Robertson

Immunology · with Bernstein · 2002–2006

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom M. Robertson trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Trinchieri

Who trusts M. Robertson overall

  1. Caroline L. Sokol
  2. J. Griffith
  3. A. Moretta
  4. A. Luster

Papers from M. Robertson's perspective

Ordered by how strongly the researchers M. Robertson trusts endorse each paper. Same corpus, a different order for every researcher.

  1. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma (British Journal of Haematology)
  2. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (New England Journal of Medicine)
  3. A phase 2 study of bortezomib in relapsed, refractory myeloma. (New England Journal of Medicine)
  4. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients… (Journal of Clinical Oncology)
  5. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. (Journal of Clinical Oncology)
  6. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. (Journal of Clinical Oncology)
  7. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants (Science)
  8. Adaptive Immune Features of Natural Killer Cells (Nature)
  9. Cytokine activation induces human memory-like NK cells.
  10. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. (Blood)

Their papers